Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sight Sciences, Inc. (Nasdaq: SGHT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an eyecare technology company focused on interventional glaucoma and dry eye devices, Sight Sciences uses SEC reports to communicate financial results, capital arrangements, and key corporate developments.
Investors can review Form 8-K filings where the company reports quarterly and year-to-date financial highlights, raises or updates revenue and adjusted operating expense guidance, and describes restructuring plans intended to reduce operating expenses and improve cost efficiencies. Other 8-Ks detail amendments to the company’s senior secured term loan facility with Hercules Capital, including changes to the interest-only period and tranche availability.
Filings also disclose material corporate events such as workforce reductions, executive transitions, and board changes. For example, the company has reported promotions of senior executives, entry into amended and restated employment agreements, and the resignation of directors, along with related compensation and severance terms.
These SEC documents complement the company’s press releases on clinical and reimbursement milestones for its OMNI® Surgical System, SION® Surgical System, and TearCare® System. On Stock Titan, users can access real-time updates from EDGAR and use AI-powered summaries to quickly understand the main points of lengthy filings, including quarterly (10-Q) and annual (10-K) reports when available, as well as Form 4 insider transaction reports.
AI-generated overviews help explain complex sections of Sight Sciences’ filings in plain language, highlight changes in guidance or capital structure, and point out disclosures that may be relevant to the company’s Surgical Glaucoma and Dry Eye segments. This allows readers to navigate detailed regulatory documents more efficiently while focusing on the aspects of SGHT’s business that matter most to them.
Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein reported an open-market sale of 25,874 shares of common stock at a weighted average price of $3.48 per share. According to the filing, these shares were sold to cover her tax liability arising from the vesting of restricted stock units.
After this transaction, Bauerlein holds 701,621 shares of common stock, including 156,788 shares currently held and 544,833 shares that will be acquired upon the future vesting and settlement of unvested restricted stock units.
Sight Sciences, Inc. director and Chief Technology Officer David Badawi reported an open-market sale of 8,168 shares of Common Stock at a weighted average price of $3.48 per share. According to the footnotes, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this transaction, Badawi's reported holdings total 1,990,290 shares, consisting of 1,804,359 shares of common stock and 185,931 shares that will be acquired upon future vesting and settlement of restricted stock units. The sale represents a small portion of his overall position.
Sight Sciences EVP Taylor Brenton sold 2,869 shares of Common Stock at a weighted average price of $3.70 per share. According to the disclosure, these shares were sold solely to cover tax liabilities arising from the vesting of restricted stock units, rather than as a discretionary portfolio move.
After this tax-related sale, Brenton holds 267,807 shares, including 31,631 shares of Common Stock and 236,176 additional shares that are scheduled to be received upon future vesting and settlement of RSUs. This indicates the transaction affected only a small portion of his overall equity exposure to the company.
Sight Sciences, Inc. President and CEO Paul Badawi sold 29,244 shares of common stock at a weighted average price of $3.70 per share. According to the disclosure, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
The shares were sold in multiple transactions at prices ranging from $3.63 to $3.85. After this tax-related sale, Badawi directly holds 5,544,983 shares of common stock and has an additional 606,173 shares that will be received upon future vesting and settlement of RSUs.
Reported proposed sale of 25,874 shares of Common Stock by Alison Bauerlein. The filing shows the securities are from Restricted Stock Vesting dated 03/31/2026. It also discloses prior open-market sales of 10,896 shares for $85,239.41 on 01/05/2026 and 9,647 shares for $72,175.00 on 01/06/2026.
David Y. Badawi submitted a Form 144 proposing the sale of 8,168 shares of Common Stock that vest on 03/31/2026 as restricted stock compensation. The filing also lists four dispositions in January 2026 totaling 14,496 shares across four trades, with dollar amounts shown next to each trade.
SGHT submitted a Form 144 notice reporting the planned sale of 29,244 shares of Common Stock tied to restricted stock vesting on 03/31/2026. The filing lists three dispositions by Paul Badawi in January 2026: 25,356, 11,870, and 22,362 shares with corresponding dollar amounts.
SGHT submitted a Form 144 notice disclosing proposed sales of Common Stock. The filing lists 576 shares associated with 03/30/2026 (restricted stock vesting) and 2,293 shares associated with 03/31/2026 (restricted stock vesting). The filing also reports 619 shares sold on 01/06/2026 by Brenton Taylor.
Sight Sciences, Inc. announced that the U.S. District Court for the District of Delaware issued an order preserving a jury’s verdict that Alcon willfully infringed three Sight Sciences glaucoma patents. The order awards $34 million in past monetary damages, plus supplemental damages and interest, and grants an ongoing 10% royalty on Hydrus Microstent revenue through November 10, 2028, when the last asserted patent expires. A final judgment will be entered after supplemental damages and pre-judgment interest are calculated and remains subject to appeal by Alcon. Parallel ex parte reexaminations at the USPTO could affect Sight Sciences’ ability to collect if adverse outcomes become final before the litigation is finally resolved in the company’s favor. Sight Sciences expects to record a $5.4 million success fee payable to its litigation counsel in operating expenses, which it plans to exclude from non-GAAP adjusted operating expenses.
Sight Sciences, Inc. is an eyecare technology company focused on interventional treatments for glaucoma and dry eye disease. It develops devices designed to restore the eye’s natural drainage and tear-film function, targeting large but under-served markets.
The company’s interventional glaucoma business centers on the OMNI Surgical System and the SION Surgical Instrument, which enable minimally invasive glaucoma surgery in both cataract-combination and standalone procedures. For dry eye, its TearCare system delivers controlled heat and manual gland expression to treat meibomian gland disease, supported by randomized clinical trials such as OLYMPIA and SAHARA and health-economic studies showing potential cost savings versus prescription drops.
Sight Sciences emphasizes clinical evidence, reimbursement access, and specialized sales teams in the U.S. and select international markets. As of June 30, 2025, non-affiliate market value was about $153.6 million, and 54,005,984 common shares were outstanding as of February 26, 2026.